International Pharmaceutical Regulators Programme (IPRP)

In January 2018, the two international initiatives "International Pharmaceutical Regulators Forum (IPRF)" and "International Generic Drug Regulators Programme (IGDRP)" were merged and now operate under the name "International Pharmaceutical Regulators Programme (IPRP)". For its regulatory members and observers, IPRP represents an international platform with the following aims:

  • Exchanging information and experience
  • Discussing topics that are of mutual interest, including new scientific technologies and regulatory challenges
  • Promoting the consistent implementation of ICH Guidelines
  • Promoting the potential harmonisation of regulatory requirements 

In collaboration with IPRP members, Swissmedic will work to promote convergence of regulatory requirements for new chemical and biological entities and generic medicines, identify emerging regulatory issues, align activities and share learnings. Swissmedic is actively engaged within all of IPRP’s working groups:

• Quality Working Group for Generics
• Bioequivalence Working Group for Generics
• Information sharing Working Group for Generics
• Biosimilars Working Group
• Nanomedicines Working Group
• Gene therapy Working Group
• Cell therapy Working Group
• Identification of Medicinal Products (IDMP) Working Group.

Further information on IPRP members, meeting summaries and working groups can be found on the IPRP website:

Archive Documents IGDRP / IPRF

The International Generic Drug Regulators Pilot (IGDRP) was launched in April 2012 with the aim of enhancing international collaboration in the area of the authorisation of generics. Following a three-year pilot phase, the steering committee and working groups of the International Generic Drug Regulators Programme (IGRDP) held their first meeting in Pretoria, South Africa, on 25-28 May 2015.

More information on the IGDRP:

Last modification 26.09.2019

Top of page